Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2000-04

AUTHORS

P. Riva, G. Franceschi, N. Riva, M. Casi, M. Santimaria, M. Adamo

ABSTRACT

. The high-grade malignant gliomas (anaplastic astrocytomas and glioblastoma) have a very bad prognosis since the available methods of treatment (surgery, radiotherapy and chemotherapy) are unable to control the progression of the disease for long. The use of specific monoclonal antibodies labelled with a suitable isotope (iodine-131 or yttrium-90) represents an effective approach to hamper tumour regrowth. Some authors have injected the antibodies intravenously, or have tried to increase the tumour/background ratio with the avidin/ biotin system. In many cases the labelled monoclonal antibodies were injected directly into the tumoral bed after the operation. The authors’ experiences concern a quite large locoregional radioimmunotherapy study which was performed by using antitenascin antibodies labelled initially with 131I and more recently with 90Y. The clinical results demonstrate the ability of this technique to control, for a long time, the growth of these tumours. The glioblastoma median survival was prolonged to 25 months (131I group) or 31 months (90Y group). The response rate (which comprises PR, CR and NED) was 47.1% (glioblastoma 131I group) or 40% ( glioblastoma 90Y group). In many cases a significant tumour shrinking effect was radiologically demonstrated. The use of 90Y proved more favourable in bulky lesions, and reduced the radioprotection problems. More... »

PAGES

601-609

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s002590050549

DOI

http://dx.doi.org/10.1007/s002590050549

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1010084610

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/10853818


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Brain Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glioma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nuclear Medicine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radioimmunotherapy", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Medicine; \u201cM. Bufalini\u201d Hospital, Cesena, and 1st Oncologico Romagnolo, Italy, IT", 
          "id": "http://www.grid.ac/institutes/grid.414682.d", 
          "name": [
            "Department of Nuclear Medicine; \u201cM. Bufalini\u201d Hospital, Cesena, and 1st Oncologico Romagnolo, Italy, IT"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Riva", 
        "givenName": "P.", 
        "id": "sg:person.01177547630.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01177547630.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Medicine; \u201cM. Bufalini\u201d Hospital, Cesena, and 1st Oncologico Romagnolo, Italy, IT", 
          "id": "http://www.grid.ac/institutes/grid.414682.d", 
          "name": [
            "Department of Nuclear Medicine; \u201cM. Bufalini\u201d Hospital, Cesena, and 1st Oncologico Romagnolo, Italy, IT"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Franceschi", 
        "givenName": "G.", 
        "id": "sg:person.01371354664.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01371354664.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Medicine; \u201cM. Bufalini\u201d Hospital, Cesena, and 1st Oncologico Romagnolo, Italy, IT", 
          "id": "http://www.grid.ac/institutes/grid.414682.d", 
          "name": [
            "Department of Nuclear Medicine; \u201cM. Bufalini\u201d Hospital, Cesena, and 1st Oncologico Romagnolo, Italy, IT"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Riva", 
        "givenName": "N.", 
        "id": "sg:person.0646254024.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646254024.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Medicine; \u201cM. Bufalini\u201d Hospital, Cesena, and 1st Oncologico Romagnolo, Italy, IT", 
          "id": "http://www.grid.ac/institutes/grid.414682.d", 
          "name": [
            "Department of Nuclear Medicine; \u201cM. Bufalini\u201d Hospital, Cesena, and 1st Oncologico Romagnolo, Italy, IT"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Casi", 
        "givenName": "M.", 
        "id": "sg:person.01347076462.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01347076462.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Medicine; \u201cM. Bufalini\u201d Hospital, Cesena, and 1st Oncologico Romagnolo, Italy, IT", 
          "id": "http://www.grid.ac/institutes/grid.414682.d", 
          "name": [
            "Department of Nuclear Medicine; \u201cM. Bufalini\u201d Hospital, Cesena, and 1st Oncologico Romagnolo, Italy, IT"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Santimaria", 
        "givenName": "M.", 
        "id": "sg:person.01212244412.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01212244412.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Medicine; \u201cM. Bufalini\u201d Hospital, Cesena, and 1st Oncologico Romagnolo, Italy, IT", 
          "id": "http://www.grid.ac/institutes/grid.414682.d", 
          "name": [
            "Department of Nuclear Medicine; \u201cM. Bufalini\u201d Hospital, Cesena, and 1st Oncologico Romagnolo, Italy, IT"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Adamo", 
        "givenName": "M.", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf01058463", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010423284", 
          "https://doi.org/10.1007/bf01058463"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s007010050301", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000434655", 
          "https://doi.org/10.1007/s007010050301"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1993.25", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024101687", 
          "https://doi.org/10.1038/bjc.1993.25"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-3-642-79952-5_11", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030281175", 
          "https://doi.org/10.1007/978-3-642-79952-5_11"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6690345", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002751259", 
          "https://doi.org/10.1038/sj.bjc.6690345"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-1-4615-5357-1_78", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012791996", 
          "https://doi.org/10.1007/978-1-4615-5357-1_78"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.3109/13550289809114522", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070986059", 
          "https://doi.org/10.3109/13550289809114522"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002590050397", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020962118", 
          "https://doi.org/10.1007/s002590050397"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2000-04", 
    "datePublishedReg": "2000-04-01", 
    "description": "Abstract. The high-grade malignant gliomas (anaplastic astrocytomas and glioblastoma) have a very bad prognosis since the available methods of treatment (surgery, radiotherapy and chemotherapy) are unable to control the progression of the disease for long. The use of specific monoclonal antibodies labelled with a suitable isotope (iodine-131 or yttrium-90) represents an effective approach to hamper tumour regrowth. Some authors have injected the antibodies intravenously, or have tried to increase the tumour/background ratio with the avidin/ biotin system. In many cases the labelled monoclonal antibodies were injected directly into the tumoral bed after the operation. The authors\u2019 experiences concern a quite large locoregional radioimmunotherapy study which was performed by using antitenascin antibodies labelled initially with 131I and more recently with 90Y. The clinical results demonstrate the ability of this technique to control, for a long time, the growth of these tumours. The glioblastoma median survival was prolonged to 25 months (131I group) or 31 months (90Y group). The response rate (which comprises PR, CR and NED) was 47.1% (glioblastoma 131I group) or 40% ( glioblastoma 90Y group). In many cases a significant tumour shrinking effect was radiologically demonstrated. The use of 90Y proved more favourable in bulky lesions, and reduced the radioprotection problems.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s002590050549", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1297401", 
        "issn": [
          "1619-7070", 
          "1619-7089"
        ], 
        "name": "European Journal of Nuclear Medicine and Molecular Imaging", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "27"
      }
    ], 
    "keywords": [
      "malignant gliomas", 
      "high-grade malignant gliomas", 
      "monoclonal antibodies", 
      "tumor/background ratios", 
      "radioimmunotherapy approaches", 
      "median survival", 
      "worse prognosis", 
      "tumor regrowth", 
      "specific monoclonal antibodies", 
      "clinical results", 
      "radioimmunotherapy studies", 
      "significant tumors", 
      "tumoral bed", 
      "response rate", 
      "antitenascin antibodies", 
      "antibodies", 
      "tumors", 
      "gliomas", 
      "months", 
      "nuclear medicine", 
      "treatment", 
      "suitable isotope", 
      "prognosis", 
      "lesions", 
      "background ratio", 
      "bulky lesions", 
      "disease", 
      "progression", 
      "survival", 
      "cases", 
      "medicine", 
      "biotin system", 
      "use", 
      "available methods", 
      "experience concerns", 
      "regrowth", 
      "effective approach", 
      "long time", 
      "radioprotection problems", 
      "study", 
      "role", 
      "rate", 
      "effect", 
      "ability", 
      "concern", 
      "time", 
      "ratio", 
      "authors", 
      "bed", 
      "results", 
      "growth", 
      "approach", 
      "technique", 
      "method", 
      "operation", 
      "system", 
      "problem", 
      "isotopes", 
      "avidin/ biotin system", 
      "authors\u2019 experiences concern", 
      "large locoregional radioimmunotherapy study", 
      "locoregional radioimmunotherapy study", 
      "glioblastoma median survival", 
      "locoregional radioimmunotherapy approach"
    ], 
    "name": "Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach", 
    "pagination": "601-609", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1010084610"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s002590050549"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "10853818"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s002590050549", 
      "https://app.dimensions.ai/details/publication/pub.1010084610"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:11", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_331.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s002590050549"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s002590050549'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s002590050549'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s002590050549'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s002590050549'


 

This table displays all metadata directly associated to this object as RDF triples.

220 TRIPLES      22 PREDICATES      106 URIs      89 LITERALS      13 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s002590050549 schema:about N06132889666c4032ae2e06be1c03bfb9
2 N0a2f2646b1874dffbe0e24db11a561e5
3 N3a2901fe5d5145e7ba5c44a3b86b6543
4 N4a1686119491448b8223e10a26cba4ec
5 N669de2197fe94c2faacd04837fbead3c
6 Nfe8d2999e6cb4f36a776c83ef4f625b5
7 anzsrc-for:11
8 anzsrc-for:1103
9 anzsrc-for:1112
10 schema:author N47cd04af567e4dc8a762afefbcc6ff39
11 schema:citation sg:pub.10.1007/978-1-4615-5357-1_78
12 sg:pub.10.1007/978-3-642-79952-5_11
13 sg:pub.10.1007/bf01058463
14 sg:pub.10.1007/s002590050397
15 sg:pub.10.1007/s007010050301
16 sg:pub.10.1038/bjc.1993.25
17 sg:pub.10.1038/sj.bjc.6690345
18 sg:pub.10.3109/13550289809114522
19 schema:datePublished 2000-04
20 schema:datePublishedReg 2000-04-01
21 schema:description Abstract. The high-grade malignant gliomas (anaplastic astrocytomas and glioblastoma) have a very bad prognosis since the available methods of treatment (surgery, radiotherapy and chemotherapy) are unable to control the progression of the disease for long. The use of specific monoclonal antibodies labelled with a suitable isotope (iodine-131 or yttrium-90) represents an effective approach to hamper tumour regrowth. Some authors have injected the antibodies intravenously, or have tried to increase the tumour/background ratio with the avidin/ biotin system. In many cases the labelled monoclonal antibodies were injected directly into the tumoral bed after the operation. The authors’ experiences concern a quite large locoregional radioimmunotherapy study which was performed by using antitenascin antibodies labelled initially with 131I and more recently with 90Y. The clinical results demonstrate the ability of this technique to control, for a long time, the growth of these tumours. The glioblastoma median survival was prolonged to 25 months (131I group) or 31 months (90Y group). The response rate (which comprises PR, CR and NED) was 47.1% (glioblastoma 131I group) or 40% ( glioblastoma 90Y group). In many cases a significant tumour shrinking effect was radiologically demonstrated. The use of 90Y proved more favourable in bulky lesions, and reduced the radioprotection problems.
22 schema:genre article
23 schema:inLanguage en
24 schema:isAccessibleForFree false
25 schema:isPartOf N24219be515cd46f1b7d67c4e9ffe1d56
26 N6f766589175343f8bfe2db42545bb728
27 sg:journal.1297401
28 schema:keywords ability
29 antibodies
30 antitenascin antibodies
31 approach
32 authors
33 authors’ experiences concern
34 available methods
35 avidin/ biotin system
36 background ratio
37 bed
38 biotin system
39 bulky lesions
40 cases
41 clinical results
42 concern
43 disease
44 effect
45 effective approach
46 experience concerns
47 glioblastoma median survival
48 gliomas
49 growth
50 high-grade malignant gliomas
51 isotopes
52 large locoregional radioimmunotherapy study
53 lesions
54 locoregional radioimmunotherapy approach
55 locoregional radioimmunotherapy study
56 long time
57 malignant gliomas
58 median survival
59 medicine
60 method
61 monoclonal antibodies
62 months
63 nuclear medicine
64 operation
65 problem
66 prognosis
67 progression
68 radioimmunotherapy approaches
69 radioimmunotherapy studies
70 radioprotection problems
71 rate
72 ratio
73 regrowth
74 response rate
75 results
76 role
77 significant tumors
78 specific monoclonal antibodies
79 study
80 suitable isotope
81 survival
82 system
83 technique
84 time
85 treatment
86 tumor regrowth
87 tumor/background ratios
88 tumoral bed
89 tumors
90 use
91 worse prognosis
92 schema:name Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach
93 schema:pagination 601-609
94 schema:productId N47515fa868fe46bbabee5538b3ca20e0
95 N6cd9f80ac4ad429eab777dbe1e781df6
96 Nb1c26f18140541ccbf5772363874883e
97 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010084610
98 https://doi.org/10.1007/s002590050549
99 schema:sdDatePublished 2022-01-01T18:11
100 schema:sdLicense https://scigraph.springernature.com/explorer/license/
101 schema:sdPublisher N9c38c6a16d6b4cebb46e71fba7cb88fb
102 schema:url https://doi.org/10.1007/s002590050549
103 sgo:license sg:explorer/license/
104 sgo:sdDataset articles
105 rdf:type schema:ScholarlyArticle
106 N06132889666c4032ae2e06be1c03bfb9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Antibodies, Monoclonal
108 rdf:type schema:DefinedTerm
109 N0a2f2646b1874dffbe0e24db11a561e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Brain Neoplasms
111 rdf:type schema:DefinedTerm
112 N1638c3e2a9294ed6a319e18abc0c6977 rdf:first sg:person.01347076462.98
113 rdf:rest N7608412602a940aca90fb870bf987c47
114 N24219be515cd46f1b7d67c4e9ffe1d56 schema:volumeNumber 27
115 rdf:type schema:PublicationVolume
116 N264296a08e124f3590c1568b5ef9890c schema:affiliation grid-institutes:grid.414682.d
117 schema:familyName Adamo
118 schema:givenName M.
119 rdf:type schema:Person
120 N3a2901fe5d5145e7ba5c44a3b86b6543 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Radioimmunotherapy
122 rdf:type schema:DefinedTerm
123 N47515fa868fe46bbabee5538b3ca20e0 schema:name pubmed_id
124 schema:value 10853818
125 rdf:type schema:PropertyValue
126 N47cd04af567e4dc8a762afefbcc6ff39 rdf:first sg:person.01177547630.17
127 rdf:rest Nacef9397e9c04c958f7f98154779fa0d
128 N4a1686119491448b8223e10a26cba4ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Humans
130 rdf:type schema:DefinedTerm
131 N669de2197fe94c2faacd04837fbead3c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Nuclear Medicine
133 rdf:type schema:DefinedTerm
134 N6cd9f80ac4ad429eab777dbe1e781df6 schema:name doi
135 schema:value 10.1007/s002590050549
136 rdf:type schema:PropertyValue
137 N6f766589175343f8bfe2db42545bb728 schema:issueNumber 5
138 rdf:type schema:PublicationIssue
139 N7608412602a940aca90fb870bf987c47 rdf:first sg:person.01212244412.79
140 rdf:rest N871e2f68576a42eeb0a49c2085de1378
141 N871e2f68576a42eeb0a49c2085de1378 rdf:first N264296a08e124f3590c1568b5ef9890c
142 rdf:rest rdf:nil
143 N975300d05ee2474bb8f7e3613a03c1e1 rdf:first sg:person.0646254024.48
144 rdf:rest N1638c3e2a9294ed6a319e18abc0c6977
145 N9c38c6a16d6b4cebb46e71fba7cb88fb schema:name Springer Nature - SN SciGraph project
146 rdf:type schema:Organization
147 Nacef9397e9c04c958f7f98154779fa0d rdf:first sg:person.01371354664.54
148 rdf:rest N975300d05ee2474bb8f7e3613a03c1e1
149 Nb1c26f18140541ccbf5772363874883e schema:name dimensions_id
150 schema:value pub.1010084610
151 rdf:type schema:PropertyValue
152 Nfe8d2999e6cb4f36a776c83ef4f625b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Glioma
154 rdf:type schema:DefinedTerm
155 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
156 schema:name Medical and Health Sciences
157 rdf:type schema:DefinedTerm
158 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
159 schema:name Clinical Sciences
160 rdf:type schema:DefinedTerm
161 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
162 schema:name Oncology and Carcinogenesis
163 rdf:type schema:DefinedTerm
164 sg:journal.1297401 schema:issn 1619-7070
165 1619-7089
166 schema:name European Journal of Nuclear Medicine and Molecular Imaging
167 schema:publisher Springer Nature
168 rdf:type schema:Periodical
169 sg:person.01177547630.17 schema:affiliation grid-institutes:grid.414682.d
170 schema:familyName Riva
171 schema:givenName P.
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01177547630.17
173 rdf:type schema:Person
174 sg:person.01212244412.79 schema:affiliation grid-institutes:grid.414682.d
175 schema:familyName Santimaria
176 schema:givenName M.
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01212244412.79
178 rdf:type schema:Person
179 sg:person.01347076462.98 schema:affiliation grid-institutes:grid.414682.d
180 schema:familyName Casi
181 schema:givenName M.
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01347076462.98
183 rdf:type schema:Person
184 sg:person.01371354664.54 schema:affiliation grid-institutes:grid.414682.d
185 schema:familyName Franceschi
186 schema:givenName G.
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01371354664.54
188 rdf:type schema:Person
189 sg:person.0646254024.48 schema:affiliation grid-institutes:grid.414682.d
190 schema:familyName Riva
191 schema:givenName N.
192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646254024.48
193 rdf:type schema:Person
194 sg:pub.10.1007/978-1-4615-5357-1_78 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012791996
195 https://doi.org/10.1007/978-1-4615-5357-1_78
196 rdf:type schema:CreativeWork
197 sg:pub.10.1007/978-3-642-79952-5_11 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030281175
198 https://doi.org/10.1007/978-3-642-79952-5_11
199 rdf:type schema:CreativeWork
200 sg:pub.10.1007/bf01058463 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010423284
201 https://doi.org/10.1007/bf01058463
202 rdf:type schema:CreativeWork
203 sg:pub.10.1007/s002590050397 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020962118
204 https://doi.org/10.1007/s002590050397
205 rdf:type schema:CreativeWork
206 sg:pub.10.1007/s007010050301 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000434655
207 https://doi.org/10.1007/s007010050301
208 rdf:type schema:CreativeWork
209 sg:pub.10.1038/bjc.1993.25 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024101687
210 https://doi.org/10.1038/bjc.1993.25
211 rdf:type schema:CreativeWork
212 sg:pub.10.1038/sj.bjc.6690345 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002751259
213 https://doi.org/10.1038/sj.bjc.6690345
214 rdf:type schema:CreativeWork
215 sg:pub.10.3109/13550289809114522 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070986059
216 https://doi.org/10.3109/13550289809114522
217 rdf:type schema:CreativeWork
218 grid-institutes:grid.414682.d schema:alternateName Department of Nuclear Medicine; “M. Bufalini” Hospital, Cesena, and 1st Oncologico Romagnolo, Italy, IT
219 schema:name Department of Nuclear Medicine; “M. Bufalini” Hospital, Cesena, and 1st Oncologico Romagnolo, Italy, IT
220 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...